Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. Deris A, Sohrabi-Haghighat M. PLoS One 2023;18:e0282646.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Deris A, Sohrabi-Haghighat M. Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PLoS One 2023;18:e0282646.
PMID: 36893142